Does Lithium Prevent Alzheimer’s Disease?

  title={Does Lithium Prevent Alzheimer’s Disease?},
  author={Orestes V. Forlenza and Vanessa de Jesus de Paula and Rodrigo Machado-Vieira and Breno S. Diniz and Wagner F. Gattaz},
  journal={Drugs \& Aging},
Lithium salts have a well-established role in the treatment of major affective disorders. More recently, experimental and clinical studies have provided evidence that lithium may also exert neuroprotective effects. In animal and cell culture models, lithium has been shown to increase neuronal viability through a combination of mechanisms that includes the inhibition of apoptosis, regulation of autophagy, increased mitochondrial function, and synthesis of neurotrophic factors. In humans, lithium… 
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders
In the last two decades, a growing body of evidence has shown that lithium has several neuroprotective effects. Several neurobiological mechanisms have been proposed to underlie these clinical
Lithium: Implications for Neuropsychiatry and Wellness
The bulk of evidence suggests that the optimum level of lithium intake is more than most people get from food and drinking water, and the question of whether the prospect of adding lithium to drinking water is realistic is realistic.
Long-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [¹⁸F]FDG-PET study.
Lithium modulates several intracellular pathways related to neuroplasticity and resilience against neuronal injury. These properties have been consistently reported in experimental models, and
Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration.
The present findings support the lithium protective effects against the cognitive impairment that characterizes the brain cholinergic depletion.
Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons
Long-term lithium treatment increases membrane phospholipid metabolism in neurons through the activation of total, c- and iPLA2, and this effect is more prominent at sub-therapeutic concentrations of lithium.
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and Therapy
E enlightening the detailed biological ability and complicated mechanisms of action of BDNF in the context of AD would provide a future BDNF-related remedy for AD, such as increment in the production or release of endogenous BDNF by some drugs or BDNF mimics.
Glycogen Synthase Kinase-3 as a Therapeutic Target for Cognitive Dysfunction in Neuropsychiatric Disorders
The role of GSK-3 as a regulator of cognitive-dependent functions is summarised, current preclinical and clinical evidence of the potential of G SKS-3 inhibitors as therapeutic agents for cognitive impairments in neuropsychiatric disorders are examined, and some insight is offered into the current obstacles that are impeding the clinical use of selective GK3 inhibitors in the treatment of cognitive impairment.
Chronic Lithium Treatment Increases Telomere Length in Parietal Cortex and Hippocampus of Triple-Transgenic Alzheimer's Disease Mice.
It is suggested that chronic lithium treatment does affect telomere maintenance, but the magnitude and nature of this effect depend on the working concentrations of lithium and characteristics of the tissue.


Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease.
The findings of the present investigation indicated that beneficial effects of the lithium treatment might reduce the necessity of enhanced GDNF expression in the CNS in early AD.
Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.
In AD patients treated with lithium, a significant increase of BDNF serum levels, and additionally a significant decrease of ADAS-Cog sum scores in comparison to placebo-treated patients, were found.
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.
The evidence reviewed here suggests that lithium's neurotrophic effects in BD are an example of an old molecule acting as a new proof-of-concept agent, which will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses.
Lithium Fails to Protect Dopaminergic Neurons in the 6-OHDA Model of Parkinson’s Disease
The results suggest that GSK3 is minimally involved in the neurodegeneration in the rat 6-OHDA model of PD, and lithium was unable to alleviate 6- OHDA-induced degeneration of SNpc dopaminergic neurons.
Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease
New regulatory effects of lithium over GSK3b are suggested, contributing to the better understanding of its mechanisms of action, offering a new and complementary explanation for Gsk3b modulation and reinforcing its potential for the inhibition of key pathological pathways in Alzheimer’s disease.
Neuroprotective and neurotrophic effects of long term lithium treatment in mouse brain
Results suggested that chronic Li administration, at therapeutic doses, has a neuroprotective/neurotrophic properties and its therapeutic mechanism doesn’t implicate GSK3 inactivation.
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
The notion that lithium treatment may lead to reduced hyperphosphorylation of tau protein after a short 10-week treatment in the Alzheimer's disease target population is not supported.
Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.
It is reported that both lithium as well as valproic acid (VPA) inhibit beta-amyloid peptide (Abeta) production in HEK293 cells stably transfected with Swedish amyloid precursor protein (APP)(751) and in the brains of the PDAPP (APP(V717F)) Alzheimer's disease transgenic mouse model at clinically relevant plasma concentrations.